ArticlePloS one2013
Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy.Diabetes/metabolism research and reviews · 2025Review
- Diabetes-induced redistribution of mast cells to the adventitia in ascending aortic aneurysms.Biomolecules & biomedicine · 2025Article
- Impact of chronic hyperglycaemia on the coronary microcirculation - benefits of targeting IL-36 and diet reversal.Basic research in cardiology · 2025Article
- Retraction: Myocardial Remodeling in Diabetic Cardiomyopathy Associated with Cardiac Mast Cell Activation.PloS one · 2024Article
- Mechanisms of liver fibrosis in metabolic syndrome.eGastroenterology · 2023Article
- Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.Advanced drug delivery reviews · 2021Review
- Diabetic fibrosis.Biochimica et biophysica acta. Molecular basis of disease · 2021Review
- Mast Cells in Diabetes and Diabetic Wound Healing.Advances in therapy · 2020Review
- Basic Mechanisms of Diabetic Heart Disease.Circulation research · 2020Review
- Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy.Translational research : the journal of laboratory and clinical medicine · 2019Article
- Substance P-mediated cardiac mast cell activation: An in vitro study.Neuropeptides · 2019Article
- Mast Cells in Cardiac Fibrosis: New Insights Suggest Opportunities for Intervention.Frontiers in immunology · 2019Review
- Monoamine oxidase-dependent endoplasmic reticulum-mitochondria dysfunction and mast cell degranulation lead to adverse cardiac remodeling in diabetes.Cell death and differentiation · 2018Article
- Mast Cells: Key Contributors to Cardiac Fibrosis.International journal of molecular sciences · 2018Review
- Astragalus polysaccharides protect cardiac stem and progenitor cells by the inhibition of oxidative stress-mediated apoptosis in diabetic hearts.Drug design, development and therapy · 2018Article
- Oncostatin M-induced cardiomyocyte dedifferentiation regulates the progression of diabetic cardiomyopathy through B-Raf/Mek/Erk signaling pathway.Acta biochimica et biophysica Sinica · 2016Article
- Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.Molecular and cellular biochemistry · 2015Article
- Inhibition of JNK by compound C66 prevents pathological changes of the aorta in STZ-induced diabetes.Journal of cellular and molecular medicine · 2014Article
Corrections and comments
- Retraction · 2024-06-11Author Unresponsive · Concerns/Issues about Image · Duplication of/in Image · Euphemisms for Duplication ·
- Retracted
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy is a specific disease process distinct from coronary artery disease and hypertension. The disease features cardiac remodeling stimulated by hyperglycemia of the left ventricle wall and disrupts contractile functions. Cardiac mast cells may be activated by metabolic byproducts resulted from hyperglycermia and then participate in the remodeling process by releasing a multitude of cytokines and bioactive enzymes. Nedocromil, a pharmacologic stabilizer of mast cells, has been shown to normalize cytokine levels and attenuate cardiac remodeling. In this study, we describe the activation of cardiac mast cells by inducing diabetes in normal mice using streptozotocin (STZ). Next, we treated the diabetic mice with nedocromil for 12 weeks and then examined their hearts for signs of cardiac remodeling and quantified contractile function. We observed significantly impaired heart function in diabetic mice, as well as increased cardiac mast cell density and elevated mast cell secretions that correlated with gene expression and aberrant cytokine levels associated with cardiac remodeling. Nedocromil treatment halted contractile dysfunction in diabetic mice and reduced cardiac mast cell density, which correlated with reduced bioactive enzyme secretions, reduced expression of extracellular matrix remodeling factors and collagen synthesis, and normalized cytokine levels. However, the results showed nedocromil treatments did not return diabetic mice to a normal state. We concluded that manipulation of cardiac mast cell function is sufficient to attenuate cardiomyopathy stimulated by diabetes, but other cellular pathways also contribute to the disease process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.